natgillin/translations-raw huggingface dataset:
In certain embodiments, the expression of the one or more polynucleotides by the target cells exceeds the relative sum of the expression of the one or more polynucleotides achieved by the first lipid nanoparticle and the second lipid nanoparticle that comprise the pharmaceutical composition when the target cells are contacted with the first lipid nanoparticle and the second lipid nanoparticle independently of the other. 
Farmaceutski pripravak za isporuku polinukleotida tipa informacijske RNK (iRNK) do jedne ili više ciljnih stanica, naznačen time da navedeni pripravak sadrži iRNK i mješavinu najmanje prve lipidne nanočestice 1 druge lipidne nanočestice, pri čemu prva lipidna nanočestica sadrži iRNK; 1 pri čemu prva lipidna nanočestica sadrži najmanje jedan lipid jasno različit od druge lipidne nanočestice.
the starting suspension is the product of a process comprising combining the lipid component and the protein component; 
(ili) početna suspenzija je proizvod postupka koji obuhvaća miješanje lipidne komponente i proteinske komponente;
Treatment in accordance with the invention may be symptomatic or prophylactic. 
Liječenje u skladu s izumom može biti simptomatičko ili profilaktičko.
The hydrophilic binder should be suitable for complete miscibility with COMPOUND A and upon formulation dissolution, serve as a precipitation inhibitor of COMPOUND A. Suitable hydrophilic binders for inclusion in the inner phase include copovidone, hydroxypropylmethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, and methacrylate copolymer, polyethylene oxide, HPMC acetate succinate, HPMC phthalate. Copovidone is especially useful as the hydrophilic binder. 
Kruta oralna farmaceutska formulacija prema zahtjevu 1, naznačena time što je hidrofilno vezivo odabrano iz skupine koju čine kopovidon, hidroksipropilmetilceluloza, polivinilpirolidon, hidroksipropilceluloza, metakrilatni kopolimer, polietilen oksid, hidroksipropilmetilceluloza (HPMC) acetat sukcinat, hidroksipropilmetilceluloza (HPMC) ftalat. Kruta oralna farmaceutska formulacija prema zahtjevu 3, naznačena time što hidrofilno vezivo je kopovidon.
"aryl" refers to 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system; 
"heteroaril" se odnosi na 4-člani, 5-člani, 6-člani ili 7-člani monociklički prsten,
The soft chewable veterinary composition of claim 1, wherein the binder is polyvinylpyrrolidone, a co-polymer of vinyl acetate and vinyl pyrrolidone or a polyethylene glycol, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 5, naznačen time, da vezivo je polivinilpirolidon, križno vezani polivinilpirolidon, kopolimer vinilacetata i vinilpirolidona, ili polietilenglikol, ili njihova kombinacija, još poželjnije, polivinilpirolidon ili polietilenglikol, ili njihova kombinacija.
A pharmaceutical composition comprising an effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema bilo kojem od patentnih zahtjeva 20, 22, 24, 26 ili 28 i farmaceutski prihvatljiv nosač.
The use of claim 4, wherein the cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases are mediated by abnomally activated B-lymphocytes, T-lymphocytes or both. 
Uporaba u skladu s patentnim zahtjevom 4, naznačena time, da su rakovi, tumori, upalne bolesti, autoimune bolesti ili imunološki posredovane bolesti posredovane abnormalno aktiviranim B-limfocitima, T-limfocitima ili oboje.
According to another preferred embodiment of the process according to the present invention, step d) is carried out in that both the ground calcium carbonate and/or the precipitated calcium carbonate of step b) and the hydrophobising agent of step c) are provided in the dry state or in a solvent. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje se korak d) provodi tako da su i mljeveni kalcijev karbonat i/ili taloženi kalcijev karbonat iz koraka b) i sredstvo za hidrofobizaciju iz koraka c) u suhom stanju ili u otapalu.
A method of treating Parkinson's disease (PD) or a related disorder in a mammalian subject in need thereof, the method comprising simultaneously, separately or sequentially administering to the subject an effective amount of at least two compounds selected from the group consisting of carbetapentane, rilmenidine, buphenine, carvedilol, cimetidine, ciprofibrate, dexbrompheniramine, ifenprodil, metformin, mexiletine, moxonidine, nitrendipine, and triamterene, or salts, prodrugs, derivatives of any chemical purity, or sustained release formulation thereof, wherein the subject has Parkinson's disease or a related disorder and wherein the related disorder is selected from the group consisting of tremor, bradykinesia, rigidity, postural instability, and abnormal gait. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se najmanje jedan preteča dopamina bira iz skupine koju čine levodopa i melevodopa, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem, najmanje jedan agonist dopaminskih receptora se bira iz skupine koju čine talipeksol, piribedil, rotigotin, bromokriptin, pergolid, kabergolin, lisurid, pramipeksol, ropinirol ili apomorfin, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem, a najmanje jedan inhibitor enzima koji metaboliziraju dopamin se bira iz skupine koju čine selegilin i rasagilin, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem.
iii-2) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean tmax of vildagliptin of 2.59 hr +/- 1.4 hr following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study), and/or 
Vildagliptina od 2.59 h +/- 1.44 h nakon oralne primjene navedenog dozirnog oblika na dan 9 pacijentu koji je bio tretiran navedenim dozirnim oblikom jednom dnevno od dana | i pri čemu je navedenom pacijentu bio serviran ADA doručak unutar 30 minuta jutarnje primjene navedenog dozirnog oblika, i/ili kruti oralni dozirni oblik koji sadrži oko 100 mg vildagliptin slobodne baze ili odgovarajuću količinu njegove farmaceutski prihvatljive soli, te podlogu, pri čemu navedeni dozirni oblik pruža srednju vrijednost max.
The process according to any one of the preceding claims, wherein the aqueous medium to be treated is contacted with 0.05 to 20 wt.-%, preferably with 0.5 to 10 wt.-% and most preferably with 0.1 to 5 wt.-% of the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate, based on the total weight of the aqueous medium. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se vodeni medij koji se obrađuje dovodi u kontakt s 0.05 do 20 tež-%, poželjno s 0.5 do 10 tež-% i najpoželjnije s 0.1 do 5 tež-% hidrofobiranog prirodnog kalcijevog karbonata i/ili hidrofobiranog taložnog kalcijevog karbonata, bazirano na ukupnoj težini vodenog medija.
The compound of claim 11, wherein the additional anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir. 
Spoj za primjenu prema zahtjevu 9, naznačen time da je dodatni antivirusni agens izabran iz grupe koja se sastoji od laninamivira, oseltamivira, zanamivira, i peramivira.
The method of claim 1 wherein the feedstock is washed and/or leached prior to pressurized pretreatment; or wherein the feedstock is soaked in an acetic acid containing liquid from a subsequent step of the pretreatment prior to pressurized pretreatment. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se sirovinu ispire i/ili moči prije predobrade pod tlakom; ili gdje se sirovinu namače u tekućini koja sadrži octenu kiselinu iz naknadnog koraka predobrade prije predobrade pod tlakom.
The instrument of Claim 4, wherein the proximal end of the infusion/aspiration tip (104) extends in a direction along the longitudinal axis to a point adjacent to the infusion port (106). 
Instrument prema zahtjevu 4, naznačen time, da se bliži kraj infuzijskog/aspiracijskog vrha (104) proteže u smjeru uzduž uzdužne osi do točke koja graniči s infuzijskim priključkom (106).
Method for the certification of electronic mail delivery, according to claim 2, characterized in that before storing it in the database (12), the processing unit (11) performs a decomposition of the copy of the first electronic mail in at least: origin, destination, attachments. 
Metoda za potvrđivanje dostave elektronske pošte, u skladu s patentnim zahtjevom 2, karakterizirana na način da, prije pohrane u bazu podataka (12), jedinica za obradu (11) provodi rastavljanje preslike prve elektronske pošte na najmanje: izvornik, odredište, privitci.
A pesticidal mixture according to claim 1, wherein the mixture comprises an agricultural acceptable carrier and optionally a surfactant. 
Pesticidna smjesa prema zahtjevu 1 ili zahtjevu 2, naznačena time što smjesa sadrži poljoprivredno prihvatljiv nosač i prema potrebi surfaktant.
If, on the other hand, the adjusted dose is equal to a ceiling value, (D + k.D) or MaxDose, or to the bottom value (D - k.D) for at least one of the cartridges used, with k being different from zero and MaxDose being different from HD, then medication waste is not eliminated but is at least statistically reduced, i.e. 
Metoda sukladno bilo kojoj od zaštita 8-10, naznačena time što je prva doza jednaka najmanjem od (Cont /n)i najmanje jedne gornje vrijednosti, a druga doza je jednaka najvećem od (Cont / (n + 1)) i najmanje jedne donje vrijednosti.
a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and (i) citrate and/or (ii) acetate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 25°C for 3 to 6 months of about less than 5%; 
(b) tekući vodeni farmaceutski pripravci koja sadržava terapeutski učinkovitu količinu Adalimumaba u puferiranoj otopini koja sadržava L-histidin i citrat, a spomenuta formulacija ima pH od 5 do 5,5 i ima sadržaj agregiranih vrsta Adalimumaba, nakon skladištenja pri 25 "€ tijekom 3 do 6 mjeseci, manje od 5 %;
The expansion joint according to claim 10, wherein the first dividing member of the upper portion, the second dividing member of the upper portion, the first vertically oriented corrugated plate of the lower portion, and the second vertically oriented corrugated plate of the lower portion are formed of a substantially rigid material. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time da su razdjelni elementi (4, 6) gornjeg dijela i valovite ploče (15, 17) donjeg dijela oblikovani od u biti čvrstog materijala; posebno od metalnog materijala; posebno od čelika.
• is either free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM; 
• ne sadrži sredstvo fosfatnog pufera ili sadrži sustav fosfatnog pufera u koncentraciji do najviše 0.1 mM;
W is selected from: 
W je izabran od: i)
The range of proliferation was calculated from the positive (vehicle plus EGF) and negative (vehicle minus EGF) control values. 
Raspon proliferacije izračunat je iz pozitivnih (nosač + EGF) i negativnih (nosač - EGF) kontrolnih vrijednosti.
The method according to claim 1, wherein the breast cancer is a locally advanced breast cancer. 
Kombinacija za uporabu prema zahtjevu 1, gdje je rak dojke lokalno uznapredovali rak dojke.
The epoxide compounds of the formula (III) can be prepared by epoxidation of an alkene of the formula (II) above. 
Epoksidni spojevi formule (III) se mogu pripremiti epoksidacijom alkena formule (II) gore.
Pharmaceutical active ingredients with abuse potential are known to the person skilled in the art, as are the quantities thereof to be used and processes for the production thereof, and may be present in the dosage form according to the invention as such, in the form of the corresponding derivatives thereof, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof, as racemates or stereoisomers. 
Farmaceutske djelatne tvari s potencijalom zlouporabe su poznate stručnjaku isto kao i količine koje treba primijeniti i postupci za njihovu pripremu i kao takve mogu biti u obliku svojih tome odgovarajućih derivata, osobito estera ili etera, ili u obliku odgovarajućih fiziološki podnošljivih spojeva, osobito u obliku njihovih odgovarajućih soli ili solvata, kao racemati ili stereoizomeri u obliku davanja lijeka prema izumu.
hetAra is a 5-6 membered heteroaryl ring having 1-4 nitrogen atoms; and 
(ii) - 5-6-eročlani heteroarilni prsten s 1-2 atoma dušika;
4, with at least one of the mutations selected from the group consisting of amino acid Q at position 1 being replaced by N, amino acid S at position 28 being replaced by N, amino acid S at position 31 being replaced by T, amino acid V at position 33 being replaced by L, amino acid D at position 34 being replaced by A, amino acid Y at position 49 being replaced by F, amino acid T at position 53 being replaced by N, amino acid Y at position 55 being replaced by A, amino acid L at position 89 being replaced by Q, and amino acid N at position 93 being replaced by Y. Such an antibody is preferably characterized as comprising the heavy chain constant region the amino acid sequence shown in SEQ ID NO. 
4, gdje se najmanje jednu od mutacija bira iz skupine koju čine aminokiselina Q na položaju 1, zamijenjena s N, aminokiselina S na položaju 28, zamijenjena s N, aminokiselina S na položaju 31, zamijenjena s 'T, aminokiselina V na položaju 33, zamijenjena s L, aminokiselina D na položaju 34, zamijenjena s A, aminokiselina Y na položaju 49, zamijenjena s F, aminokiselina T na položaju 53, zamijenjena s N, aminokiselina Y na položaju 55, zamijenjena s A, aminokiselina L na položaju 89, zamijenjena s Q, te aminokiselina N na položaju 93, zamijenjena SY.
The system of claim 17, further comprising an operating system configured to control the residuum hydroconversion reactor system (13) to produce the mixed heavy hydrocarbon fraction (35) having a nickel content of less than about 70 ppmw, a vanadium content of less than about 70 ppmw, an asphaltenes/Conradson Carbon Residue (CCR) ratio of less than 0.7 to 1, and a total sulfur content of less than about 24,000 ppmw. 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da nadalje sadržava operativni sustav konfiguriran za kontrolu reaktorskog sustava rezidualne hidrokonverzije (13) za proizvodnju miješane teške ugljikovodične frakcije (35) koja ima sadržaj nikla manji od oko 70 ppmw, sadržaj vanadija manje od oko 70 ppmw, omjer asfalten / Conradson ugljični ostatak (CCR) manji od 0,7 do 1, 1 ukupni sadržaj sumpora manji od oko 24,000 ppmw.
The polypeptide according to any of claims 1 to 4, the nucleic acid according to claim 5 or the pharmaceutical composition according to any of claims 8 to 13 for use in a method of treating or preventing a Borrelia infection, particularly a B. burgdorferi s.s., B. garinii, B. afzelii, B. andersoni, B. bavariensis, B. bissettii, B. valaisiana, B. lusitaniae, B. spielmanii, B. japonica, B. tanukii, B. turdi or B. sinica infection, preferably a B. burgdorferi s.s., B. afzelii or B. garinii infection. 
Polipeptid sukladno bilo kojem patentnom od zahtjeva 1 do 4, nukleinska kiselina prema zahtjevu 5 ili farmaceutski pripravak prema bilo kojem od zahtjeva 8 do 13 za uporabu u postupku liječenja ili prevencije infekcije Borrelia, osobito B. burgdorferi s.s., B. garinii, B. afzelii, B. andersoni, B. bavariensis, B. bisseltii, B. valaisiana, B. lusitaniae, B. spielmanii, B. japonica, B. tanukii, B. turdi ili B. sinica infekcije, poželjno B. burgdorferi s.s., B. afzelii ili B. garinii infekcije.
Composition for use according to claim 10, wherein said skin lesions characterised by epidermal hyperproliferation and dermal damage are selected from the group consisting of acne and keratosis. 
Postupak prema zahtjevu 10, naznačen time da je metabolički modulator odabran iz skupine koja sadrži polarna aprotička otapala, DMSO, aceton, N,N-dimetilformamid, i acetonitril.
The process of claim 1, comprising the steps of: purifying IL-2 by RP-HPLC; precipitating the IL-2; adding SDS to the precipitated IL-2, to give a final SDS concentration of at least 500µg SDS per mg of IL-2; removing any precipitated IL-2 covalent multimers by gel filtration; and reducing the SDS concentration to remove some but not all SDS from the composition, to give a composition that contains between 95-250µg SDS per mg of IL-2. 
Proces prema patentnom zahtjevu 1, naznačen time, da se sastoji od stupnjeva: pročišćavanje IL-2 pomoću reverzne faze (RP- Reverse Phase) HPLC; taloženje IL-2; dodavanje SDS istaloženom IL-2 da dade konačnu koncentraciju SDS od barem 500ug SDS po mg IL-2; odstranjivanje bilo kojeg od istaloženih kovalentno vezanih IL-2 multimera pomoću gel filtracije; i smanjivanje koncentracije SDS da se odstrani nešto, ali ne sav SDS iz sastava, da dade sastav koji sadrži između 95-250ug SDS po mg IL-2.
A pharmaceutical formulation comprising a powder to be dispersed in an aqueous vehicle and suitable for parenteral administration to neonates affected by brain injury, said powder consisting of: 
PATENTNI ZAHTJEVI Farmaceutska formulacija koja sadrži prašak koji se dispergira u vodenom vezikulu i pogodno za parenteralno davanje novorođenčadi koji imaju ozljedu mozga, rečeni prašak sadrži: i)
A pharmaceutical composition, comprising a compound selected from the group consisting of: 
Spoj prema zahtjevu 1, koji je odabran od skupine koja se sastoji od:
An indolizine derivative as claimed in claim 1, which is selected from the group consisting of 
Derivat indolizina prema zahtjevu 8, koji je izabran iz grupe koja obuhvaća:
Bupropion and trazodone for use in the treatment of female sexual dysfunction (FSD) in a subject. 
Bupropion i trazodon naznačen time da je za uporabu za liječenje ženske seksualne disfunkcije (FSD) kod subjekta.
At the mouth end 15 of tube 44 there is a low efficiency cellulose acetate filter plug 45. In the embodiment shown in Figure 2, an aluminum macrocapsule 52 is used to enclose a granular substrate 54 and tobacco 56. 
U realizaciji koja je prikazana na sl. 9, koristi se aluminijska makrokapsula 52 tipa koji je prikazan na sl. 5 za uklapanje granularnog supstrata 54 i čepa 56 duhana.
The polypeptide according to claim 1, wherein the polypeptide maintains 50 % of its maximum substrate conversion capacity when the conversion is done for 60 minutes at a temperature of 60°C or higher. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time, da polipeptid zadržava 50 % svoje maksimalne snage pretvorbe supstrata kada se pretvorba provodi u trajanju od 60 minuta na temperaturi od 60 °C ili višoj.
The invention is further illustrated by the following examples: 
Ovaj izum daljnje ilustriraju sljedeći primjeri:
The rapamycin carbohydrate derivatives may act as prodrugs. That is, they may be substantially without immunosuppressive activity themselves, but in vivo be converted to rapamycin which then exhibits an immunosuppressive effect. 
Ugljikohidratni derivati rapamicina mogu djelovati kao prolijekovi, to jest, mogu postojati sami po sebi u biti bez imunosupresivne aktivnosti, ali in vivo se mogu prevesti u rapamicin koji potom iskazuje imunosupresivni učinak.
Diketene (22.5 mL, 293 mmol) was added slowly via dropping funnel followed by addition of TMSCl (37.2 mL, 293 mmol) in the same manner. 
Polako se doda diketen (22,5 ml, 293 mmol) kroz lijevak za kapanje, a zatim se doda TMSCI (37,2 ml, 293 mmol), na isti način.
The solution is acidified with HCl(c) and brought to pH=4. 
Otopinu se zakiseli s HCI i namjesti na pH=4.
The compound for use according to claim 7, wherein the compound is administered to the subject in a pharmaceutical composition which comprises at least one water-insoluble filler, at least one water-soluble filler, at least one binder, and at least one lubricant, wherein the water-insoluble filler is microcrystalline cellulose, the water-soluble filler is lactose monohydrate, the binder is hydroxypropyl methylcellulose, and the lubricant is glyceryl behenate. 
HR P20191647 T1 Spoj za uporabu prema patentnom zahtjevu 7, naznačen time što se spoj daje subjektu u farmaceutskom pripravku koji sadrži najmanje jedno punilo koje nije topivo u vodi, najmanje punilo koje je topivo u vodi, najmanje jedno vezivo, te najmanje jedan lubrikant, pri čemu punilo koje nije topivo u vodi je mikrokristalna celuloza, punilo koje je topivo u vodi je laktoza monohidrat, vezivo je hidroksipropil metilceluloza, i lubrikant je gliceril behenat.
The method for use in a dry powder formulation according to claim 4, providing a metered nominal dose of aclidinium equivalent to from 100 to 1000 micrograms of aclidinium bromide per inhalation. 
Aklidinij za primjenu u obliku formulacije suhog praha prema zahtjevu 4, pri čemu je odmjerena nominalna doza aklidinija jednaka od 100 do 1000 mikrograma aklidinijevog bromida po inhalaciji, poželjno od 200 do 400 mikrograma aklidinijevog bromida.
Lozenges were prepared using the method of Example 1, having the following constitution:— 
Tablete su pripremljene primjenom postupka iz Primjera 1, sa slijedećim sastavom:
Product for the control of odour, characterized in that it contains surface reacted calcium carbonate as defined in any one of claims 1 to 8 for the control of odour, wherein the surface-reacted calcium carbonate is a reaction product of natural ground or precipitated calcium carbonate with carbon dioxide and one or more acids in an aqueous medium, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source; and wherein the product is selected from diapers, feminine hygiene products such as pads, panty liners, sanitary napkins and tampons; incontinence products; deodorant formulations; nonwoven products such as wipes and medical products; plastic packaging material; mono and multilayer structures; permeable bags; adsorption pads; animal litter; construction and building material; preparations of compost and organic fertilizers. 
Proizvod za kontrolu mirisa, naznačen time da sadrži površinski reagirani kalcijev karbonat kako je definirano u bilo kojem od zahtjeva 1 do 8 za kontrolu mirisa, pri čemu površinski reagirani kalcijev karbonat je reakcijski produkt prirodnog mljevenog ili istaloženog kalcijevog karbonata s ugljikovim dioksidom i jednom ili više kiselina u vodenom mediju, pri čemu ugljikov dioksid nastaje in situ obradom s kiselinom i/ili se dovodi iz vanjskog izvora; i pri čemu je proizvod odabran iz skupa koji čine pelene, ženski higijenski proizvodi kao što su ulošci, jednodnevni ulošci, higijenski ulošci i tamponi; proizvodi za inkontinenciju; formulacije za dezodoriranje; netkani proizvodi HR P20170990 T1 kao što su maramice i medicinski proizvodi; plastični materijal za pakiranje; jednoslojne i višeslojne strukture; propusne vrećice; adsorpcijski jastučići; životinjski otpad; konstrukcijski i građevinski materijal; pripravci od komposta i organska gnojiva.
The method of claim 5, wherein the composition is injected in one or more split doses. The method of claim 6, wherein the injection sites are located about 5 cm apart from each other. 
Pripravak prema zahtjevima 6 ili 7, naznačen time da su mjesta za inokulaciju ili injekciju na tijelu smještena na udaljenosti najmanje 5 cm jedno od drugoga.